Delving into the Latest Updates on Acetaminophen with Synapse

Overview

Basic Info

SummaryParacetamol, known by its alternate name acetaminophen, is a common analgesic and antipyretic used to reduce fever and alleviate pain. Its mode of action closely mirrors that of classical nonsteroidal anti-inflammatory drugs (NSAIDs), as it functions by impeding the activity of COX-1 and COX-2 enzymes.Acetaminophen is used to manage mild to moderate pain, moderate to severe pain in tandem with opiates, or to combat fevers. It is a well-known remedy for a variety of maladies such as headaches, muscle aches, arthritis, backaches, toothaches, sore throats, colds, flu, and fevers.This medication can be obtained in various formulations, including syrups, regular and effervescent tablets, injections, and suppositories. Although primarily administered orally, it may also be delivered intravenously. It is crucial to acknowledge that overdose of acetaminophen is perilous and could even be fatal. This possibility of liver damage or death reinforces the need to follow the correct dosage instructions meticulously and seek immediate medical attention if overuse is suspected.Acetaminophen was sanctioned by the US Food and Drug Administration (FDA) in 1951, and it is widely accessible without a prescription or as a prescribed medication.

Drug Type

Small molecule drug

Synonyms

4'-hydroxyacetanilide, 4-(Acetylamino)phenol, 4-ACETAMIDOPHENOL

+ [91]

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

AnalgesiaFeverPain

Inactive Indication

Acute migraineAcute PainAnesthesia+ [24]

Originator Organization

Dandong Yichang Pharmaceutical Co., Ltd.

Active Organization

Sanofi-Aventis Australia Pty Ltd.

Dandong Yichang Pharmaceutical Co., Ltd.Hikma Pharmaceuticals USA, Inc.

+ [11]

Inactive Organization

Tianjin Hankang Pharmaceutical Biotechnology Co. Ltd.

GSK Plc

Johnson & Johnson Holdco (NA), Inc.

+ [21]

License Organization

Seelos Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1966),

FeverPain

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS Registry103-90-2

Neuro-inflammation response plays an important role in the development of acute ischemic stroke(AIS). The aim of this study was to conduct a prospective randomized controlled study on the effect of acetaminophen on long-term neurological prognosis in AIS patients undergoing endovascular treatment(EVT). The primary outcome was the incidence of neurological independence (mRS 0-2, modified Rankin scale) at 90 days after surgery. The secondary outcome measures were early neurological outcome (NIHSS score at 7 days after surgery or at discharge) and the incidence of symptomatic intracerebral hemorrhage during hospitalization. This study explored the effect of acetaminophen on the prognosis of neurological function of patients, and the expected results provide evidence of safety and effectiveness for acetaminophen to improve the prognosis of neurological function of patients, and provide theoretical and practical basis for the subsequent "new use of old drugs" of acetaminophen and large sample and multi-center clinical research or clinical application.

Start Date01 May 2025

Sponsor / Collaborator

Beijing Tiantan Hospital

100 Clinical Results associated with Acetaminophen

Login to view more data

100 Translational Medicine associated with Acetaminophen

Login to view more data

100 Patents (Medical) associated with Acetaminophen

Login to view more data

58,886

Literatures (Medical) associated with Acetaminophen

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Patterns of analgesic utilisation among people with knee osteoarthritis: a cohort study using UK primary care data

Article

Author: Knaggs, Roger David ; Gran, Sonia ; Taqi, Aqila

Background:

Osteoarthritis (OA) is a prevalent disabling joint disease affecting more than 300 million people globally and knees are most commonly affected. It is associated with pain and functional limitation that adversely affect mental well-being and compromise quality of life. Analgesic use is common among patients with knee osteoarthritis (KOA), however, data on patterns of analgesics use at an individual patient level are sparse. The present study describes patterns of analgesic use, by determining the proportion of persistent users within one year of therapy initiation in patients with KOA.

Methods:

A retrospective cohort study using the clinical practice research datalink. Analgesic prescriptions for adults with an incident KOA diagnosis were captured and grouped into five exposure groups including: antidepressants, antiepileptic drugs (AEDs), opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. A persistent user was a person who used >180 defined daily doses (DDDs) per year and had prescriptions in at least three out of the four quarters of the year.

Results:

Variable proportions of patients used respective analgesic classes persistently during the first year after prescribing; 36.8% of antidepressant users, 27.0% of NSAIDs, 23.8% of AEDs, 17.5% of paracetamol and 14.9% of opioid users were persistent users. Across classes, persistent users were slightly younger, were issued more prescriptions and used higher doses of analgesics compared to non-persistent users.

Conclusion:

Between 14.9% and 36.8% became persistent analgesic users by the end of the first year after their initial prescription. The study applied meaningful clinical attributes to define persistence. This informs future research on clinical and adverse drug outcomes in persistent users compared to non-persistent users across five separate analgesic classes.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Abuse and misuse of tramadol in patients with non-oncologic pain in a region of Southern Europe

Article

Author: Cereza, G. ; Pérez-Cano, F. J. ; Rius, P. ; Rio-Aigé, K. ; Perelló, M. ; Rabanal, M.

Background:

Tramadol can cause dependence even within the recommended dose range. Its use has increased recently, especially in patients with chronic pain, and although a growing body of literature identifies a non-therapeutic use, patterns of misuse of tramadol is so far limited.

Methods:

Two-year observational and cross-sectional study (January 2020 - December 2021) was conducted in 75 community pharmacies from Catalonia. To estimate the potential abuse and misuse of tramadol by patients visiting community pharmacy, and to establish the demographic characteristics of the tramadol users, a validated questionnaire based on the Finch criteria was designed. A total of 251 cases were registered.

Results:

Data show that women were more involved (56.6%) and the highest proportion was found in the age interval of 46-65 years (42.6%). The combination of tramadol and paracetamol was reported in 54.6% of the cases and 73.7% corresponded to immediate-release tablets. In 93.6% of the cases, the request was preceded by previous use. Conversely, young men showed a higher non-prescription request for tramadol, reporting acute pain (p < 0.05). These results indicate that there is non-therapeutic use among patients who visit community pharmacies for information on two profiles.

Conclusion:

This study shows that being an aged woman and suffering from chronic pain seems to involve a risk of generating dependence on tramadol. Likewise, a suspicion of recreational use of tramadol by young people has also been identified. There is a need to investigate how to manage chronic pain, given its complexity and take into account the risk of misuse that may come with tramadol. The involvement of characteristics such as gender as well as the pharmaceutical form in the development of tramadol misuse also needs to be analysed deeply. It is mandatory to evaluate the criteria for prescribing tramadol and initiatives to improve the knowledge of the health professionals and the population.

01 Dec 2025·Current Pain and Headache Reports

Ultrasound Guided Genicular Nerve Blocks for Pain Management Following Total Knee Replacement: A Narrative Review

Review

Author: Tassin, Joseph P ; Frolov, Mark V ; Ahmadzadeh, Shahab ; Kaye, Alan D ; Kataria, Saurabh ; Shekoohi, Sahar ; Upshaw, William C ; Corrent, Jacob M ; Armstrong, Catherine J ; Patel, Hirni ; Patil, Shilpadevi ; D'Antoni, James V ; Behara, Raju

PURPOSE OF REVIEW:

Total knee replacement (TKR) is a common procedure to alleviate pain in patients with severe osteoarthritis of the knee after failed conservative treatment. While generally safe, postoperative pain is a significant issue many patients experience following surgery.

RECENT FINDINGS:

To control postoperative pain, numerous treatments may be administered which may be given preoperatively, intraoperatively, or postoperatively. These treatments include medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids. Additionally, peripheral nerve blocks (PNB) may be performed prior to total knee replacement to limit pain after the surgery. A specific type of PNB done prior to total knee replacement is the genicular nerve block (GNB) which targets five genicular nerves that innervate different parts of the knee joint. This type of block is designed to prevent pain impulses from being sent to the central nervous system from the knee without affecting movement of the lower extremity by sparing efferent nerves innervating muscles. PubMed was used to identify the studies found in this review that are less than 5 years old using the search term "genicular nerve block clinical studies." Most studies compared GNB alone compared to other blocks, however some used GNB in combination with other blocks, most at a maximum of 48 h postoperative. GNB is typically performed by anesthesiologists under ultrasound guidance to ensure accurate placement of the block. Clinical studies have shown that GNB is effective in controlling pain following TKR leading to lower pain scores following surgery as well as a reduced level of opioid consumption. Additionally, GNB has shown reduced motor weakness following TKR compared to other types of PNBs allowing earlier mobilization of patients. However, more studies are needed to further investigate the efficacy of GNB compared to other PNBs to treat postoperative pain following TKR.

551

News (Medical) associated with Acetaminophen

27 May 2025

·www.fiercepharma.com

FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset

Unlike a post-review rejection in the form of a complete response letter, an refuse to file letter means the FDA has declined to evaluate Savara’s application as submitted. Despite hiring a commercial chief and sponsoring disease awareness efforts last year, Savara will have to wait a while longer for a potential approval of its inhaled lung disease asset molgramostim.The FDA has slapped Savara with a refuse to file (RTF) letter after the biotech in March applied for approval of molgramostim in the rare disease autoimmune pulmonary alveolar proteinosis (aPAP).Unlike a post-review rejection in the form of a complete response letter, an RTF letter means the FDA has declined to evaluate Savara’s application as submitted.The FDA has determined that Savara’s initial filing was “not sufficiently complete to permit substantive review,” the biotech said in a Monday press release. The regulator has in turn asked Savara to provide additional chemistry, manufacturing and controls (CMC) data, suggesting some sort of production hang-up played a part in the FDA’s decision.The FDA did not flag any safety concerns related to molgramostim, nor did it request or recommend additional efficacy studies, Savara explained. Savara plans to request a meeting with the FDA in the next 30 days.“Based on our understanding of the letter, we are confident we can thoroughly address the agency’s request and expect to resubmit our [biologics license application] in the fourth quarter of 2025,” Savara CEO Matt Pauls said in a statement. The company is already in the process of generating the CMC data requested by the FDA, Pauls added.“We remain highly confident in our program for autoimmune PAP and believe that our clinical data demonstrate that Molbreevi improves pulmonary gas transfer and respiratory health-related quality of life in this rare disease,” the CEO said, referring to molgramostim by its intended trade name.Savara is developing molgramostim to treat aPAP, a rare disease that clogs the air sacs in the lungs, potentially leading to serious complications like lung fibrosis and the need for a lung transplant. As a granulocyte-macrophage colony-stimulating factor, molgramostim is designed to work by clearing surfactant—a mixture of fat and proteins in the lungs—from the alveoli, or air sacs, in the organs.The drug is delivered via an investigational nebulizer specifically designed by Germany’s PARI Pharma to work with molgramostim, Savara said in its release. Savara has been working on molgramostim for years now, facing various struggles along the way, though the company appeared to believe an approval was in reach as it started making commercial preparations last year.In September, Savara hired Orchard Therapeutics veteran Braden Parker as its chief commercial officer. Parker was primarily brought on to assist with molgramostim’s potential launch, which the company had positioned at the time for late 2025 or 2026.And, in October, Savara also sponsored an episode of “The Balancing Act," a morning talk show that airs on Lifetime, highlighting the stories of patients with rare and genetic diseases. The primary focus of the sponsored program was aPAP, molgramostim’s intended indication.Savara’s continued devotion to molgramostim comes after the company underwent a major pipeline shake-up in 2020, during which it scrapped multiple other assets to hone its focus on aPAP.

Drug ApprovalAccelerated Approval

27 May 2025

·www.einpresswire.com

SciSparc Announces Publication of Japanese Patent Application

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA) that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide. “This patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug,” said Oz Adler, Chief Executive Officer of SciSparc. “This drug candidate combines paracetamol, a widely used pain reliever and fever reducer, with PEA, a natural compound that boosts the body’s endocannabinoid system. By working synergistically, the combination may reduce the required paracetamol dose, minimizing risks like liver damage while improving outcomes for acute, chronic, and neuropathic pain, as well as fever.” About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the novel pharmaceutical combination of paracetamol and PEA and that the patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common drug. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact: IR@scisparc.com Tel: +972-3-6167055 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

22 May 2025

·www.echemi.com

196 Drug Samples Fail CDSCO Tests One Deca-Durabolin Sample Declared Spurious

In a concerning development, 196 drug samples have failed quality tests conducted by the Central Drugs Standard Control Organization (CDSCO), with one sample flagged as spurious. The spurious drug, a Nandrolone Decanoate injection marketed under the name Deca-Durabolin, was found to be manufactured by an unauthorized entity using a brand name owned by another company. The Union Health Ministry clarified that the sample was collected from Bihar and failed due to issues with its identification and assay parameters. Deca-Durabolin, an anabolic steroid widely used for treating conditions like osteoporosis and anemia, is marketed in India by Zydus Healthcare, following its acquisition of the brand from Merck in 2016. Of the 196 samples classified as “Not of Standard Quality” (NSQ), 60 were flagged by central laboratories, while 136 samples were identified by state laboratories. These include commonly used drugs such as Nimesulide tablets, Paracetamol tablets, and Cefpodoxime Proxetil tablets, manufactured by various pharmaceutical firms. The ministry emphasized that these failures are specific to the tested batches and do not indicate risks associated with other batches of the same drug. Regular monthly testing is conducted to ensure substandard or spurious medicines are detected and removed from the market. According to the Drugs and Cosmetics Act, 1940, a drug is deemed spurious if it is manufactured to deceive or bears the label of another drug. The CDSCO’s continuous monitoring ensures that public safety remains a top priority.

Acquisition

100 Deals associated with Acetaminophen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00217	Acetaminophen	N02BE01	DB00316

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Headache	United States	Cosette Pharmaceuticals, Inc.	09 Feb 1978
Analgesia	Japan	Iwaki Seiyaku Co., Ltd.	01 Jul 1966
Fever	China	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966
Pain	China	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Toothache	Phase 3	United States	Johnson & Johnson Holdco (NA), Inc.	19 Jul 2017
Common Cold	Phase 3	-	GSK Plc	01 Feb 2017
Pharyngitis	Phase 3	-	GSK Plc	01 Feb 2017
Episodic tension-type headache	Phase 3	United States	GSK Plc	01 Apr 2013
Acute Pain	Phase 3	United States	Mallinckrodt Plc	01 Jan 2008
Pain, Postoperative	Phase 3	United States	Mallinckrodt Plc	01 Nov 2006
Uterine Neoplasms	Phase 3	United States	Mallinckrodt Plc	01 Nov 2006
Acute migraine	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Mar 2006
Osteoarthritis, Hip	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	18 Oct 2005
Diabetic Neuropathies	Phase 3	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00585559 (CTgov)	Phase 3	Aneurysm, Intracranial Berry, 1 \| Vasospasm, Intracranial	44	N-acetylcysteine (N-acetylcysteine IV Infusion at 0.5 gm Hourly)	pmgvvcwnou(yvpixzysko) = iajrvpnyhz ararzelojs (glwxfnfbuc, exbdwpbgvj - xpbkqyptyk) View more	-	18 Apr 2025
				Placebo+N-acetylcysteine (Placebo for N-acetylcysteine IV Infusion at 0.5 gm Hourly)	pmgvvcwnou(yvpixzysko) = mxjodwmysu ararzelojs (glwxfnfbuc, exwkvptoex - wepuuxkhpm) View more
NCT04761302 (CTgov)	Phase 4	Femoral Fractures \| Pain, Postoperative \| Tibial Fractures	167	acetaminophen+ketorolac (Group 1: Tibial Fracture Patients Receiving Intravenous Ketorolac and Oral Acetaminophen)	leejuoitom(intnvdsody) = ubtsrkkusf dyqcgiygig (pmurpxvbsn, 2.20) View more	-	04 Mar 2025
				oxycodone+morphine (Group 2: Tibial Fracture Patients Receiving Intravenous Morphine and Oral Oxycodone)	leejuoitom(intnvdsody) = xibaklvxld dyqcgiygig (pmurpxvbsn, 2.01) View more
NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	fxiuzinexc(ikxtxiqjod) = mhzpvimmla arnxgsjmxa (avjkarxuvs, tlgbqksqqv - rvmydhqwxq) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	fxiuzinexc(ikxtxiqjod) = gwfixkckhr arnxgsjmxa (avjkarxuvs, jzhpcsvdal - pqnspryodu) View more
NCT06601114 (Pubmed \| Mol Cell Pediatr)	Not Applicable	Ductus Arteriosus, Patent	256	Paracetamol	kjmjysbqhf(oamovimcvc) = lkvtcihogh drpfppsnex (xgrtycewuq )	Positive	25 Jan 2025
				Ibuprofen	kjmjysbqhf(oamovimcvc) = xfcmbwnecd drpfppsnex (xgrtycewuq )
NCT03987022 (CTgov)	Phase 4	Pain, Postoperative	66	Opioids+Dilaudid Injectable Product+Percocet+Motrin	qhgaqoocmo(hvoxucuxvq) = bulofzvujo tgkcdxwbxf (grvwywgqyp, wmpwyjsvhi - cgcqyljyrf)	-	24 Jan 2025
ESMO_ASIA2024	Not Applicable	Lung Cancer	-	Acetaminophen exposure	pyjvdabeal(psyuzewmmz) = eqcerjahpt yorejsbfab (frfhckttcp )	Positive	07 Dec 2024
NCT04291508 (ASTER, CTgov)	Phase 2	Respiratory Failure \| Critical Illness \| Sepsis ... View more	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	jayihmmyfk(kpeikxfmup) = dlaaoakmot jbccclhxkg (swpdotkltz, 10.6) View more	-	27 Sep 2024
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	jayihmmyfk(kpeikxfmup) = zjmhrlkstp jbccclhxkg (swpdotkltz, 9.5) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	ebkbfdqqnj(cbtkpsdnvq) = tqqwjvndnx mezhpyhtcu (rxfiswkxrp, hmdpilbkzk - fmdwdnnsvj) View more	-	19 Sep 2024
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	ebkbfdqqnj(cbtkpsdnvq) = kgiapbphxc mezhpyhtcu (rxfiswkxrp, jvmlnipnap - vzuclquvlw) View more
NCT04879823 (CTgov)	Phase 3	Analgesia	222	Acetaminophen+Dexamethasone+Ibuprofen (Dexamethasone)	rcabnovklw(nksseliibe) = pfjxbrrutn itoazmvkxp (hmsecwazcn, yyodxwccej - unjtmvsfae) View more	-	05 Sep 2024
				Placebo+Acetaminophen+Ibuprofen (Placebo)	rcabnovklw(nksseliibe) = tcicrdlyfi itoazmvkxp (hmsecwazcn, lodmnyxuuk - vytidnxfda) View more
NCT03929640 (MOPAC, CTgov)	Phase 3	Pain, Postoperative	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	jctidyfzqf(yrxnlkakht) = esenfzhdzn jhqfweiqeh (lujphgyuqw, 2.3) View more	-	04 Sep 2024
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	jctidyfzqf(yrxnlkakht) = jxkdjlektk jhqfweiqeh (lujphgyuqw, 2.4) View more